Exhibit 99.1
Vincerx Pharma, Inc. Announces Reverse Stock Split
Vincerx’s Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025
SAN MATEO, California — January 23, 2025 – Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address
the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that its board of directors approved a 1-for-20 reverse
stock split of its issued shares of common stock, which will be effective as of January 27, 2025 at 4:01 p.m., Eastern Time. Vincerx’s common stock will continue trading on The Nasdaq Stock Market (“Nasdaq”) under the existing
symbol (VINC) and will begin trading on a split-adjusted basis when the market opens on January 28, 2025 with a new CUSIP number. The reverse stock split was approved by Vincerx’s stockholders at a special meeting of stockholders held on
January 16, 2025.
As of the effective time of the reverse stock split, every twenty (20) issued shares of Vincerx’s common stock will be
combined, reclassified and converted into one (1) issued share of Vincerx’s common stock. This will reduce the number of shares issued from approximately 44.8 million shares to approximately 2.2 million shares, subject to
adjustment for fractional shares. No fractional shares will be issued as a result of the reverse stock split. Stockholders who would otherwise be entitled to a fractional share of common stock are instead entitled to (and with respect to holders
that have certificated shares, upon surrender to the exchange agent of certificates representing such shares) a cash payment in lieu thereof at a price equal to the stockholder’s proportionate interest in the proceeds, net of certain costs
associated with such sale, from the aggregation and sale of the fractional shares by our transfer agent. Proportionate adjustments will be made to the number of shares of common stock underlying Vincerx’s outstanding equity awards, warrants,
the number of shares issuable under its equity incentive plans and stock option plans, and other existing agreements, as well as the exercise or conversion price, as applicable. The reverse stock split will not affect the par value of the common
stock.
Continental Stock Transfer & Trust Company is acting as the exchange agent for the reverse stock split. Registered stockholders holding pre-split shares of Vincerx’s common stock in book entry form or via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the reverse stock split,
subject to such broker’s particular processes, and will not be required to take any action in connection with the reverse stock split. Stockholders holding shares of Vincerx’s common stock in certificate form will receive a transmittal
letter from Continental Stock Transfer & Trust Company with instructions after the effective date.
Additional information about the reverse
stock split can be found in Vincerx’s definitive proxy statement filed with the Securities and Exchange Commission on December 10, 2024.
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc. is a
clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. Vincerx’s pipeline consists of a next-generation ADC, VIP943, currently in Phase 1;
a small molecule drug conjugate, VIP236, which has completed its Phase 1 study; a CDK9 inhibitor, enitociclib, which has completed a Phase 1 monotherapy study; a preclinical ADC, VIP924; and
VersAptx™, a versatile, next-generation bioconjugation platform.
Vincerx is based in San Mateo,
California, and has a research facility in Monheim, Germany.
